ReviewCurrent genomics2025
Precision Medicine: Transforming Cancer Research through Targeted Therapies.
Review in Current genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Building bridges to immunotherapy: a knowledge-mapping analysis of cervical cancer organoid research.Frontiers in immunology · 2026Pooled it
- Artificial intelligence-powered liquid biopsy in cancer: a paradigm shift in cancer detection and personalized care.Cancer cell international · 2026Review
- Article
- Pharmacovigilance Evaluation of Noninfectious Myocarditis and Pericarditis in Immune Checkpoint Inhibitor Recipients Using FAERS.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precision medicine is a landmark strategy that has been changing the future of health care through matching treatment plans with each individual patient's needs and requirements. It permits the discovery of certain genetic abnormalities that cause tumors in cancer research, resulting in tailored medicines and better outcomes. The new drug development process is facilitated by precision medicine, focusing on biomarkers and patient classification because they allow for faster identification of new treatments. Emerging trends in omics technologies and Artificial Intelligence for data processing have patient-centered telemedicine applications. Ethical and privacy issues are addressed, focusing on data security and informed consent. The additional development of precision medicine offers hope for bridging gaps in healthcare delivery systems, addressing rare disease challenges, and promoting global healthcare initiatives. The revolutionizing nature of healthcare and improved patient outcomes can only be fully realized through acceptance and support of precision medicine to its fullest extent. This review evaluates various applications of precision medicine with an emphasis on how it could potentially change the paradigm of cancer research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.